Gene Silencing Therapy in Hereditary (Variant) Transthyretin Cardiac Amyloidosis: A Puzzling Case of Decreasing Pyrophosphate Uptake on Scintigraphy.
作者信息
Smiley Dia A, Einstein Andrew J, Mintz Akiva, Shetty Mrinali, Chan Nicholas, Helmke Stephen T, Bhatia Ketan, Goldner Kim, Brannagan Thomas H, Santana Denisse D, Maurer Mathew S
机构信息
Seymour, Paul, and Gloria Milstein Division of Cardiology, Department of Medicine (D.A.S., A.J.E., M.S., N.C., S.T.H., D.D.S., M.S.M.), Columbia University Irving Medical Center, New York-Presbyterian Hospital.
Department of Radiology (A.J.E., A.M., K.B., K.G.), Columbia University Irving Medical Center, New York-Presbyterian Hospital.
出版信息
Circ Cardiovasc Imaging. 2023 Aug;16(8):e015243. doi: 10.1161/CIRCIMAGING.123.015243. Epub 2023 Jun 19.
Abstract
摘要
相似文献
1
Gene Silencing Therapy in Hereditary (Variant) Transthyretin Cardiac Amyloidosis: A Puzzling Case of Decreasing Pyrophosphate Uptake on Scintigraphy.遗传性（变异型）转甲状腺素蛋白心脏淀粉样变性的基因沉默治疗：一例骨闪烁显像中焦磷酸盐摄取减少的疑难病例
Circ Cardiovasc Imaging. 2023 Aug;16(8):e015243. doi: 10.1161/CIRCIMAGING.123.015243. Epub 2023 Jun 19.
2
Tafamidis Treatment Decreases Tc-Pyrophosphate Uptake in Patients With Hereditary Ala97Ser Transthyretin Amyloid Cardiomyopathy.他法米地治疗可降低遗传性Ala97Ser转甲状腺素蛋白淀粉样心肌病患者的锝-焦磷酸盐摄取。
JACC Cardiovasc Imaging. 2023 Jun;16(6):866-867. doi: 10.1016/j.jcmg.2022.12.016. Epub 2023 Feb 8.
3
Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.与Pro24Ser转甲状腺素蛋白突变相关的遗传性心脏淀粉样变性：一例报告
J Med Case Rep. 2018 Dec 16;12(1):370. doi: 10.1186/s13256-018-1931-5.
4
Serial Technetium Pyrophosphate Scintigraphy and Multimodality Assessments After Different Doses of Tafamidis for Variant Transthyretin Cardiac Amyloidosis.不同剂量他氟米地治疗变异型转甲状腺素蛋白心脏淀粉样变性后的系列焦磷酸锝闪烁扫描和多模态评估
Circ Heart Fail. 2023 Jan;16(1):e009595. doi: 10.1161/CIRCHEARTFAILURE.122.009595. Epub 2022 Dec 21.
5
Low-sensitivity 99mTc pyrophosphate scintigraphy for hereditary transthyretin cardiac amyloidosis with Glu112Lys genotype.针对具有Glu112Lys基因型的遗传性转甲状腺素蛋白心脏淀粉样变性的低敏感性99mTc焦磷酸盐闪烁显像
Eur Heart J Cardiovasc Imaging. 2024 Feb 22;25(3):e115. doi: 10.1093/ehjci/jead295.
6
(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.(99m)Tc-焦磷酸盐闪烁显像术鉴别轻链型心脏淀粉样变性与转甲状腺素蛋白相关家族性和老年性心脏淀粉样变性。
Circ Cardiovasc Imaging. 2013 Mar 1;6(2):195-201. doi: 10.1161/CIRCIMAGING.112.000132. Epub 2013 Feb 11.
7
Monitoring of cardiac transthyretin amyloid load by [Tc]DPD scintigraphy: is it the end of the semi-quantitative evaluation?通过[锝]二膦酸盐闪烁扫描术监测心脏转甲状腺素蛋白淀粉样蛋白负荷：半定量评估时代是否终结？
Amyloid. 2022 Sep;29(3):210. doi: 10.1080/13506129.2022.2055460. Epub 2022 Mar 24.
8
Mutant Thr95Ile Transthyretin-Related Cardiac Amyloidosis With Polyneuropathy.与多神经病相关的突变型苏氨酸95异亮氨酸转甲状腺素蛋白心脏淀粉样变性
Circ J. 2019 Oct 25;83(11):2328. doi: 10.1253/circj.CJ-19-0281. Epub 2019 Jun 26.
9
Non-invasive detection and differentiation of cardiac amyloidosis using Tc-pyrophosphate scintigraphy and C-Pittsburgh compound B PET imaging.使用 Tc-焦磷酸盐闪烁扫描和 C-Pittsburgh 化合物 B PET 成像进行非侵入性心脏淀粉样变性的检测和鉴别。
Amyloid. 2020 Dec;27(4):266-274. doi: 10.1080/13506129.2020.1798223. Epub 2020 Jul 28.
10
First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.首例挪威遗传性ATTR 淀粉样变伴新型转甲状腺素蛋白变异。
Scand Cardiovasc J. 2023 Dec;57(1):2174269. doi: 10.1080/14017431.2023.2174269.
引用本文的文献
1
Impact of Tafamidis on [Tc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects.他法米地对Ala97Ser遗传性转甲状腺素蛋白淀粉样心肌病患者[锝]锝-焦磷酸盐闪烁扫描的影响：初期显著降低，长期效果稳定
Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1853-1863. doi: 10.1007/s00259-025-07079-4. Epub 2025 Jan 13.
2
Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy.应用锝-99m-焦磷酸盐单光子发射计算机断层扫描/计算机断层扫描监测遗传性转甲状腺素蛋白淀粉样心肌病患者依罗替尼治疗的变化。
J Am Heart Assoc. 2024 Jan 16;13(2):e030512. doi: 10.1161/JAHA.123.030512. Epub 2024 Jan 12.
本文引用的文献
1
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.用于治疗遗传性转甲状腺素蛋白介导的淀粉样变性多发性神经病患者的 vutrisiran 的疗效和安全性：一项随机临床试验。
Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23.
2
Cardiac microcalcifications in transthyretin (ATTR) amyloidosis.心脏微钙化在转甲状腺素蛋白（ATTR）淀粉样变性。
Int J Cardiol. 2022 Apr 1;352:84-91. doi: 10.1016/j.ijcard.2022.01.036. Epub 2022 Jan 22.
Zotero 插件